Logo image of GTBP

GT BIOPHARMA INC (GTBP) Stock Overview

NASDAQ:GTBP - US36254L3087 - Common Stock

0.945 USD
+0.02 (+1.72%)
Last: 9/5/2025, 8:19:17 PM
0.838 USD
-0.11 (-11.32%)
Pre-Market: 9/8/2025, 8:35:53 AM

GTBP Key Statistics, Chart & Performance

Key Statistics
52 Week High4.1
52 Week Low0.88
Market Cap3.36M
Shares3.56M
Float2.83M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.79
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO10-22 2013-10-22
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


GTBP short term performance overview.The bars show the price performance of GTBP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

GTBP long term performance overview.The bars show the price performance of GTBP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GTBP is 0.945 USD. In the past month the price decreased by -48.36%. In the past year, price decreased by -51.54%.

GT BIOPHARMA INC / GTBP Daily stock chart

GTBP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.07 375.50B
AMGN AMGEN INC 13.01 152.70B
GILD GILEAD SCIENCES INC 14.86 142.76B
VRTX VERTEX PHARMACEUTICALS INC 23.38 101.56B
REGN REGENERON PHARMACEUTICALS 12.56 60.77B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 80.99 45.95B
ONC BEONE MEDICINES LTD-ADR 5.99 40.63B
INSM INSMED INC N/A 30.67B
BNTX BIONTECH SE-ADR N/A 27.03B
NTRA NATERA INC N/A 23.06B
BIIB BIOGEN INC 8.79 20.62B

About GTBP

Company Profile

GTBP logo image GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Company Info

GT BIOPHARMA INC

505 Montgomery Street, 10Th Floor

San Francisco CALIFORNIA 90212 US

CEO: Anthony J. Cataldo

Employees: 1

GTBP Company Website

GTBP Investor Relations

Phone: 18003049888

GT BIOPHARMA INC / GTBP FAQ

What is the stock price of GT BIOPHARMA INC today?

The current stock price of GTBP is 0.945 USD. The price increased by 1.72% in the last trading session.


What is the ticker symbol for GT BIOPHARMA INC stock?

The exchange symbol of GT BIOPHARMA INC is GTBP and it is listed on the Nasdaq exchange.


On which exchange is GTBP stock listed?

GTBP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GT BIOPHARMA INC stock?

7 analysts have analysed GTBP and the average price target is 11.22 USD. This implies a price increase of 1087.3% is expected in the next year compared to the current price of 0.945. Check the GT BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GT BIOPHARMA INC worth?

GT BIOPHARMA INC (GTBP) has a market capitalization of 3.36M USD. This makes GTBP a Nano Cap stock.


How many employees does GT BIOPHARMA INC have?

GT BIOPHARMA INC (GTBP) currently has 1 employees.


What are the support and resistance levels for GT BIOPHARMA INC (GTBP) stock?

GT BIOPHARMA INC (GTBP) has a resistance level at 2.18. Check the full technical report for a detailed analysis of GTBP support and resistance levels.


Should I buy GT BIOPHARMA INC (GTBP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GT BIOPHARMA INC (GTBP) stock pay dividends?

GTBP does not pay a dividend.


When does GT BIOPHARMA INC (GTBP) report earnings?

GT BIOPHARMA INC (GTBP) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of GT BIOPHARMA INC (GTBP)?

GT BIOPHARMA INC (GTBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.79).


What is the Short Interest ratio of GT BIOPHARMA INC (GTBP) stock?

The outstanding short interest for GT BIOPHARMA INC (GTBP) is 9.22% of its float. Check the ownership tab for more information on the GTBP short interest.


GTBP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GTBP Financial Highlights

Over the last trailing twelve months GTBP reported a non-GAAP Earnings per Share(EPS) of -5.79. The EPS increased by 71.19% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -439.13%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)71.19%
Revenue 1Y (TTM)N/A

GTBP Forecast & Estimates

7 analysts have analysed GTBP and the average price target is 11.22 USD. This implies a price increase of 1087.3% is expected in the next year compared to the current price of 0.945.


Analysts
Analysts82.86
Price Target11.22 (1087.3%)
EPS Next Y-19.62%
Revenue Next YearN/A

GTBP Ownership

Ownership
Inst Owners13.54%
Ins Owners7.49%
Short Float %9.22%
Short Ratio2.42